Drug Discovery and Clinical Development (2022)

This MAS is aimed at professionals from academia, the pharmaceutical industry, biotechnology sector, and international organisations who wish to gain an in-depth understanding of drugs and medical devices research and development.

CHF 15’500.- for the Master
1-day-module: CHF 1’000.-
2-day-module: CHF 1’400.-
3-day-module: CHF 1’800.-

Enable health professionals to gain a strategic vision of clinical development and navigate the complexities of bringing new medicinal products to the global market

Medical doctor, biologist, pharmacist, veterinarians, nurse, biochemist and other professional involved or wishing to gain skills and knowledge in the field of drug discovery and development

Prof. Jules DESMEULES, Faculty of Medecine and Faculty of Science, Dr François CURTIN, Faculty of Medecine, University of Geneva

This programme is accredited by Swissethics, Swiss Association of Pharmaceutical Professionals, Swiss Society of Clinical Pharmacology and Toxicology, Swiss Institute for postgraduate and continuous medical education

Dr Angèle Gayet-Ageron, CC, Lecturer, Head of the Methodological Support Unit, Clinical Research Centre (CRC), University Hospitals of Geneva, Faculty of Medecine, University of Geneva

Prof. Jérôme Pugin , Vice-Dean of the Faculty of Medicine and President of the Clinical Research Center (CRC), University Hospitals of Geneva, Faculty of Medicine, University of Geneva

Dr Jocelyne Chabert , Clinical Research Associate, Clinical Research Centre (CRC), University Hospitals of Geneva, Faculty of Medicine, University of Geneva

Dr Francois Curtin , PD, Medical Director Personalised Health Programmes, Swiss Federal Institute of Technology in Zürich (ETH Zürich) & Lecturer at Hospitals of Geneva (UNIGE)

Dr Angèle Gayet-Ageron, CC, Lecturer, Head of the Methodological Support Unit, Clinical Research Centre (CRC), University Hospitals of Geneva, Faculty of Medecine, University of Geneva

Dr Victoria Rollason , PharmD, Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva and Faculty of Medicine, University of Geneva

Dr Gabriele Ackermann, Chief Scientific Officer ad interim, Therapeutic Area Head Cardiovascular, Renal & Metabolism Therapeutic Area Head Respiratory, Novartis Pharma Switzerland

Les termes utilisés pour désigner des personnes sont pris au sens générique; ils ont à la fois la valeur d’un masculin et d’un féminin.